Background: WWOX (WW domain-containing oxidoreductase) gene, located on chromosome 16q 23.3-24.1 in the region recognized as the common fragile site FRA16D is considered to be a tumor suppressor gene involved in various cancers: breast, ovarian, prostate, esophageal, lung, pancreatic, gastric and hepatic. The aim of this study was to describe (i) putative protein interactions of WWOX (ii) the molecular mechanisms of tumor suppressor activity (iii) present an overview of WWOX in relation to nervous system and breast, prostate and ovarian cancers.
INTRODUCTION
Chromosomal and genomic abnormalities aff ecting chromosome 16q have been frequently reported in cytogenetic and allelotypic studies of various epithelial tumors. Several authors have shown, that LOH of 16q, is often observed in breast carcinomas [1] [2] [3] [4] [5] . Other tumor types, such as prostate, ovarian, esophageal, lung, pancreatic, gastric and hepatic carcinomas, exhibit similar abnormalities of 16q 6, 7, 8, [14] [15] [16] [17] [18] [19] . Bednarek et al. 8 cloned and described a gene mapping a genomic region of more than 1 million nucleotide bp located on chromosome 16q23.3-24.1, in a region recognized as the common fragile site FRA16D 8 . The gene was named WWOX (synonym name: fragile site FRA16D oxido-reductase, symbol: FOR). The WWOX gene is composed of nine exons and encodes a 46 kDa protein that possesses two NH 2 -terminal WW domains and a short chain dehydrogenase domain (SDR) found in the SDR family of enzymes. WW domains are characterized by the presence of highly conserved proline and tryptophan residues [9] [10] [11] and occur in diverse types of proteins, such as Yes-associated protein, Nedd4, dystrophin, Rsp5, Pub1, FE65, Pin1, and FBPs. In common with the SH3 domain, the WW domain is characterized by its interaction with proline-containing ligands and mediating protein-protein interactions 12, 13 . The SDR family of enzymes encompasses a wide spectrum of enzymes. One important group among SDR proteins is the family of hydroxysteroid dehydrogenases. These short-chain dehydrogenase/reductases are usually involved in the metabolism of steroid hormones such as androgens and estrogens. Further, WWOX expression is up-regulated in endocrine organs such as testis, ovary and breast, indicating the importance of WWOX in these tissues 8 . A Drosophila model has been developed for the investigation of WWOX in vivo. The Drosophila DmWWOX orthologue shares 49 % identity with human WWOX and has a conserved domain structure of tandem WW domains and oxidoreductase homology. DmWWOX null mutants are viable and fertile with no obvious phenotype. However, they show increased sensitivity to ionising radiation 20 . Protection from radiation can be restored by reintroduction of either Drosophila or human WWOX. The radiation sensitivity phenotype is similar to that previously observed for Drosophila mutants p53 (ref. 21, 22 38 showed that WWOX interacts via its fi rst WW domain with the PPPY motif of p73. The tyrosine kinase, Src, phosporylates WWOX at tyrosine 33 in the fi rst WW domain and enhances its binding to p73.
The p73 protein is a structural and functional homologue of the p53 tumor suppressor protein 39, 40 . The p73 protein localizes in the nucleus, and not only recognises and binds to p53-responsive elements in the promoter regions of diverse p53-target genes such as p21 Waf1/Cip1 and Bax 41 , but can also transactivate the transcription of these target genes. WWOX localizes to the cytoplasm, and consequently overexpression of WWOX causes the sequestration of p73 in cytoplasm and increases its proapoptotic activity 38 . It is likely that loss of WWOX in tumor cells may result in reduced p73 apoptotic activity in cytoplasm 38 . Although mutations of p73 in cancer are not frequent 41 and p73-deffi cient mice exhibit no predisposition to tumors 43 , several reports have established the role of p73 in apoptosis. Its modulation of p53 function may be important in malignity development 42 . Further studies will be necessary for evaluation of the biological consequences of this association in normal and cancer cells. Interestingly, human WWOX does not bind with p53 38 whereas the murine WWOX ortholog, Wox1, interacts with p53 and Jnk1 under stress conditions 45 . Wox1 also interacts synergistically with p53 during TNF-mediated apoptosis. This proapoptotic role of Wox1 is negatively regulated by interaction with JNK 44, 45 .
WWOX-activating protein-2λ (AP-2 λ)
Aqeilan et al. 46 demonstrated a functional association between AP-2λ transcription factor and the WWOX protein. AP-2λ at 20q13.2 encodes a transcription factor and is frequently amplifi ed in breast carcinoma. WWOX binds to the PPPY motif of AP-2λ via its fi rst WW domain. Alterations of tyrosine 33 in the fi rst WW domain of WWOX or the proline-rich motif in AP-2λ dramatically reduce this interaction. This shows that WWOX expression triggers redistribution of nuclear AP-2λ to the cytoplasm and hence suppresses its transactivating function. It is suggested that WWOX tumor suppressor protein inhibits AP-2λ oncogenic activity by its sequestering into the cytoplasm.
WWOX-YES-associated protein (YAP)
Yes-associated protein (YAP) also containing WW domains was shown to associate with p73 and enhance its transcriptional activity 47 . YAP competes with WWOX for interaction with ErbB-4 and modulates its transcriptional function. YAP interacts with ErbB-4 receptor tyrosine kinase and acts as a transcriptional coactivator of the COOH-terminal fragment (CTF) of ErbB-4. Interaction of WWOX and ErbB-4 suppresses transcriptional coactivation of CTF by YAP in a dose-dependent manner. A mutant form of WWOX lacking interaction with ErbB-4 has no eff ect on ErbB-4 coactivation ErbB-4. Further, WWOX is able to inhibit coactivation of p73 by YAP. These data indicate that WWOX antagonizes the function of YAP by competing for its interaction with ErbB-4 and other targets and thus aff ects their transcriptional activity 47 .
WWOX IN RELATION TO CANCER
Low, undetectable expression or aberrant transcripts of WWOX have been reported in diff erent types of cancer and several tumor cell lines of diff erent origin 23 . The frequent deletion of WWOX in multiple tumors suggests that WWOX may act as a tumor suppressor gene 46 . Bednarek et al. 8 evaluated WWOX expression in normal human tissue by Northern blot analysis: high levels of WWOX RNA were detected in endocrine organs such as prostate, testis and ovary and weak levels were detected in small intestine, spleen and colon. Thymus, leukocytes and breast have to the contrary very low levels of WWOX RNA.
WWOX and breast cancer
In breast carcinoma, LOH on 16q was found in 50-55 % of early tumors 19, 22 . Allelic imbalances of 16q have been reported in up to two-thirds of all sporadic breast carcinomas and have been detected even in the absence of other genetic alterations. Consequently, such losses have been considered very early events in breast carcinogenesis 25 . Some authors have described 16q loss as a discriminating factor among low-grade ductal invasive, tubular, and tubulolobular carcinomas 26, 27 Bednarek et al. 28 showed that WWOX suppresses the tumorgenicity of breast cancer cells in vitro as well as in vivo. 29 also studied PR (progesterone receptor) status, but due to the limited number of ER-PR+ breast carcinomas samples, they could not confi rm that PR+ status alone correlates with high WWOX expression.
Pluciennik et al. 30 analyzed levels of WWOX expression in 132 cases of breast cancer. They showed that WWOX expression was higher in patients under 50, in ER and PR positive tumors and in tumors without lymph node metastasis. WWOX mRNA levels were also higher in tumors with a higher apoptotic index (Bcl2/Bax ratio).
Guler et al. 32 evaluated WWOX expression immunohistochemically in 97 archived breast carcinoma specimens. Decreased WWOX expression was found in 63.2 % of invasive tumors. Reduced WWOX staining was found more frequently in ER (-) or scanty positive tumors (p = 0.033) and WWOX expression in adjacent normal tissue was reduced in 32.9% of specimens, especially in patients with higher stage disease (p = 0.033). Highly reduced WWOX staining (> 10 %) in normal breast tissue was found in post-menopausal women or in breast cancer patients exposed to neoadjuvant chemotherapy, suggesting that WWOX expression may be associated with level of steroid hormone expression and can be aff ected by chemotherapy.
Guler et al. 35 also compared expression of WWOX, ErbB2 and p53 in 44 pure ductal carcinoma in situ (DCIS) cases and 31 DCIS lesions adjacent to invasive WWOX, a new potential tumor suppressor gene tumors. Statistically signifi cant loss of WWOX expression was found in 68,2 % DCIS, followed 61,3 % invasive tumors and 54,8 % DCIS adjacent to invasive tumor.
Further studies will be necessary to prove whether loss of WWOX expression is an early causative event of breast cancer, for at least in a subset of tumors or, whether this event predominantly occurs during the progression of breast carcinomas.
WWOX and prostate cancer
Chang et al. 34 postulated that progression from normal prostate to hyperplasia and non-invasive/invasive cancer stages positively correlate with up-regulation and activation of WWOX 34 . Activated Cdc42-associated kinase (Ack1) primarily phosphorylates WWOX at tyrosine 287, resulting in WWOX being targeted for ubiquitination mediated degradation. Therefore WWOX protein can be activated or inactivated via ubiquitination, by tyrosine phosphorylation at either Tyr 33 or Tyr 287 respectively. Primary androgen-independent prostate tumors but not benign prostate showed increased tyrosine-phosporylated Ack1 and decreased WWOX. These results suggest that Ack1 stimulates prostate tumorigenesis at least in part by negative regulation of the tumor suppressor WWOX 35 .
WWOX and ovarian carcinoma
Nunez et al. 36 analyzed the WWOX protein expression in normal ovaries and ovarian carcinomas (n = 444). Immunoblotting analysis of normal ovarian samples demonstrated consistently strong WWOX expression, whereas 37 % of ovarian carcinomas showed reduced or undetectable WWOX protein expression In addition, immunohistochemistry of ovarian tissue showed either no or barely detectable levels of WWOX expression in 30 % of tumors. The remaining ovarian carcinomas (70 %) were moderately to strongly positive for this protein. 
WWOX and other carcinomas
Kuroki et al. 37 showed similar tumor suppressor eff ect of WWOX in AsPc1 and Panc1 pancreatic carcinoma cells.
Allelic losses and homozygous deletions at the FRA16D common fragile site were also reported in gastric cancer 50 . Kuroki et al. 51 examined 81 primary gastric adenocarcinomas immunohistochemically for WWOX protein expression and found a lack of WWOX protein expression in 65 %. They also found a signifi cant correlation between WWOX expression and tumor histological grade, with higher-grade tumors being signifi cantly more likely to be negative for Wwox protein expression.
Several reports have described the frequent allelic losses on chromosome 16q23-24 around the FRA16D locus in hepatocellular carcinoma 16 . Park et al. 52 found that loss of the DNA copy-number confi ned to 16q23 was detected by comparative genomic hybridization in several hepatocellular carcinoma cell lines, and that WWOX protein expression was absent or diminished in 72 % of cell lines.
The WWOX gene is also altered in lung cancer 53 . In nonsmall cell lung cancer, transcripts lacking WWOX exons were detected in 26 % of tumors and in fi ve of eight cell lines 55 . WWOX allele loss occurred in 37 % of tumors, and the promoter was hypermethylated in 62.5 % of squamous cell lung carcinomas 17, 54 Fabri et al. 53 examined the tumor suppressor function of WWOX in preclinical lung cancer models. inhibitors Bcl-2 and Bcl-xL, and up-regulates p53 expression and TNF cytotoxicity 44 . Chen et al. 49 also reported, that WOX1 is expressed in the developing murine nervous system. WOX1 is diff erentially expressed during various stages of brain development. High levels of WOX1 protein have been observed in neural crest-derived structures such as cranial and spinal ganglia, pigmented skin cells, suggesting a potential role of WOX1 in promoting neuronal diff erentiation and maturation.
WWOX and neurodegenerative diseases
WWOX is likely involved in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative diseases involving neurofi brillary tangles. WWOX interacts with Tau proteins. Tau is a microtubule-associated protein that occurs mainly in neurons and is involved in neurite extension and maintenance. Although tau is a highly soluble protein and has a natively unfolded structure, it generates insoluble and hyperphosphorylated aggregates in Alzheimer's disease, which is characterized by degenerating neurons. WWOX binds Tau via its COOH-terminal short-chain alcohol dehydrogenase/reductase domain and most likely prevents 17βestradiol and enzyme-mediated Tau phosporylation in vivo. Down-regulation of WWOX in AD neurons of hippocampi induces Tau hyperphosporylation in vivo, leading to the formation of neurofi brillary tangles (NFTs) which characterize Alzheimer's disease. This suggests a protective role of WWOX in neurodegenerative disseases 48 .
CONCLUSION
Loss of WWOX expression is associated with a number of cancers including breast, ovary, testis, prostate, lung, pancreas, gastric and hepatocellular carcinomas. The role of WWOX has not yet been studied in brains tumors. In our earlier study we determined androgen receptor expression in brains tumor cell lines. It would be interesting to analyse, whether the WWOX plays a role in brain tumors.
The association of high WWOX expression to improved disease free survial, means that WWOX can be considered as a tumor suppresor gene and a new target for gene therapy 30 .
